GlassScriptPhysician profile
Deepti Vats
NPI 1932496262
$2,785.32
in general payments reported to CMS, 2019-2025
18 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.68 · 2022: $55.28 · 2023: $696 · 2024: $1,494 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $644.77 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $329.25 | 2023-2025 | Auvelity |
| Abbvie INC. | $302.91 | 2023-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $258.52 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $257.98 | 2023-2025 | Trintellix |
| Tris Pharma INC | $235.82 | 2024-2025 | Dyanavel Xr |
| Lundbeck LLC | $161.00 | 2023-2025 | Rexulti, Brintellix |
| Teva Pharmaceuticals USA, INC. | $129.02 | 2024 | Uzedy |
| E.R. Squibb & Sons, L.L.C. | $121.96 | 2024 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $96.47 | 2023-2024 | Qelbree, Qelbree |
| Tempus Ai, INC | $96.06 | 2024 | |
| Almatica Pharma LLC | $36.47 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $36.04 | 2023-2024 | Xelstrym, Secuado |
| Sunovion Pharmaceuticals INC. | $20.17 | 2019 | |
| Brainsway USA INC | $17.65 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $14.91 | 2024 | Xelstrym |
| Alkermes, INC. | $13.51 | 2019 | |
| Orexo US, INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepti Vats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.